Contest Trader

Don't miss the chance to cash-in prizes totaling

$10.000
Register here for the Ultimate demo trading competition

Inovio Pharmaceuticals halts COVID-19 vaccine trial

Inovio Pharmaceuticals halts COVID-19 vaccine trial

Its shares plummeted more than 33% after the news

As the race for finding a viable COVID-19 vaccine is getting tougher, incidents start to show up. The latest pharmaceutical company to halt the trials after AstraZeneca is Inovio Pharmaceuticals.

Earlier today, the Pennsylvania-based company announced that Phase II of the clinical trial for its potential #COVID-19 #vaccine was in “partial clinical hold.” According to the company’s statement, the pause is caused by the Food and Drug Administration (#FDA) inquiry.

At the moment, Inovio is working on answering the regulator’s questions, and the response will be available in October. Following the company’s response, the FDA has 30 days to decide if the trial can move forward or not.

The news shocked the markets, and made Inovio stock price drop more than 33% during today’s pre-market session. Since the beginning of the year, the company’s stocks have increased 413.3%, while USA500 added 21%.

Read about AstraZeneca’s situation here!

Sources: marketwatch.com, finance.yahoo.com


This information prepared by za.capex.com is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.

This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation or the particular needs of any recipient.

You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.

This information may not be published, circulated, reproduced or distributed in whole or in part to any other person without the Company’s prior written consent. Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of za.capex.com